Scientific opportunities generally arise when two or more research areas converge and/or advances in methodology occur. This occurred at the turn of the 19th century in the field of infectious bacterial and fungal diseases. As we draw near to the 21st century, research in the laboratory is providing us with both critical information on mechanisms of carcinogenesis and new technological advancements, including those in immunology, biochemistry, and molecular biology. Investigations in the field of epidemiology have clearly demonstrated the importance of environmental exposure to carcinogens and have identified populations at high cancer risk. It is now practical to integrate laboratory determinations into classic epidemiological approaches. Several markers, e.g., carcinogen-DNA adducts, related to tumor initiation and perhaps to tumor conversion, are currently being evaluated. We also need to develop indicators of tumor promotion and progression. The potential of biochemical and molecular epidemiology to predict cancer risk in an individual prior to the onset of clinically evident cancer provides an exciting new opportunity in cancer research and prevention.
Introduction
The topic of this conference is a facet of an expanding area of cancer research-the biochemical and molecular epidemiology of cancer (1, 2) . This multidisciplinary area combines epidemiological and laboratory approaches. Its primary goal is to identify individuals at high cancer risk by obtaining evidence of high exposure to carcinogens leading to pathobiological lesions in target cells and/or increased oncogenic susceptibility due to either inherited or acquired host factors. Clinical and epidemiological studies have identified populations at high cancer risk, and in many cases also the etiological agents, e.g., tobacco smoke as the major cause of lung cancer and asbestos as the primary etiological agent for mesothelioma. Laboratory studies have extended these epidemiological findings by identifying specific carcinogens found in complex mixtures and have provided us with a better understanding of the pathogenesis of the multistage carcinogenic process.
The concepts of tumor initiation, promotion, conversion, and progression have developed from studies in experimental carcinogenesis and are schematically rep-*Laboratory of Human Carcinogenesis, Division of Cancer Etiology, National Cancer Institute, Bethesda, MD 20205. resented in Figure 1 . This simplified diagram can be used as intellectual framework to consider the stages at which carcinogen-DNA adducts may play a role in the multistage process of carcinogenesis. Assuming that these adducts lead to genetic lesions, including mutations, tumor initiation and conversion are the stages where our attention should be focused. The earliest events in chemical carcinogenesis, i.e., tumor initiation, are considered to include exposure to the carcinogen, transport of the carcinogen to the target cell, activation to its ultimate carcinogenic metabolite if the agent is a procarcinogen, and DNA damage leading to an inherited change and the preneoplastic "initiated" cell. Tumor conversion is an updated version of an old concept, i.e., benign tumors can convert to malignant tumors. Indirect evidence for this view is based on the finding of microinvasive carcinoma in putative preneoplastic lesions such as squamous metaplasia in the respiratory tract and adenomas in the large intestine. Recent studies using the mouse skin carcinogenesis model suggest that conversion of a benign tumor to a malignant one requires another genetic event in that DNA-damaging and mutagenic agents enhance the frequency and hasten the conversion of benign papillomas to squamous cell carcinomas (3) . Therefore, carcinogen-DNA adducts may be important in both the early (tumor initiation) MULTISTAGE (6) . There is also increasing amount of data which suggests that chemical carcinogens may cause both direct DNA damage, i.e., carcinogen-DNA adducts, and indirect DNA damage by causing formation of free radicals and superoxides that react with DNA and cause molecular lesions, e.g., thymine glycol (7) . Carcinogens can damage membranes and initiate the arachidonic acid cascade and the release of lipid peroxidation aldehydes, such as 4-hydroxyalkenals (8) that bind to DNA. Phthalates and hypolipidemic drugs, including clofibrate, apparently act through an indirect mechanism by causing proliferation of peroxisomes and a subsequent increase in superoxides (9) . Measures of indirect DNA damage are needed, e.g., the development of monoclonal antibodies to thymine glycol in DNA (10) .
The carcinogenicity and mutagenicity of chemicals may be dependent on more than one metabolite. For ex- (17) , who assayed aflatoxin B,-modified guanine in the urine of rats exposed to aflatoxin B1, Autrup et al. (18) detected these adducts in urine of Africans who were ingesting mycotoxin-contaminated food. Indirect DNA Animal models provide invaluable information in studies of carcinogenesis. Extrapolation of this information from experimental animals to humans remains, however, an problematic endeavor. Most scientists consider the qualitative extrapolation to be accurate, i.e., a chemical that is carcinogenic in experimental animals is likely to be carcinogenic in humans. The current debate centers on the question of quantitative extrapolation, i.e., the carcinogenic potency of a chemical. In my opinion, this question will not be resolved by mathematical modeling but will require both a better understanding of the mechanisms of carcinogenesis obtained from comparative studies by using the strategy schematically illustrated in Figure 3 . For example, responses to carcinogens, tumor promoters, anticarcinogens, etc., can be compared in tissues and cells maintained in the same controlled in vitro setting from humans and experimental animals. Over the last decade, Table 5) . One of the advantages of these approaches is that they can be specific for both carcinogenic agent and target cell type. Antisera, both monoclonal and polyclonal, have been produced to a variety of specific carcinogen-DNA adducts (20, 21) and also to DNA lesions caused by ionizing radiation, e.g., thymine glycol (10), and ultraviolet radiation, e.g., thymidine dimers (22, 23) . Highly sensitive enzyme immunoassays have been developed to measure adducts in isolated DNA from carcinogen-exposed tissues (24) and in histological and cytological preparations (25) (26) (27) . These immunoassays gain their specificity from the antibodyantigen reaction which is geometrically amplified by an enzyme conjugated to one of the immunoreactants, usually the antibody (Fig. 4) . P32-Nucleotide postlabeling and thin-layer chromatography (28) , high pressure liquid chromatography of DNA hydrolysates (29) (30) (31) , and synchronous fluorescence spectrophotometry (32) niques complement both one another and also the measurement of adducts by enzyme immunoassays. In preliminary studies (33, 34) , benzo(a)pyrene diol epoxide-DNA adducts have been detected in tissue and peripheral blood samples from people exposed to benzo(a)pyrene. There is wide interindividual variation in the amounts of adducts measured, which may be a reflection of differences in environmental exposure to benzo(a)pyrene, ratio of metabolic activation and deactivation, and DNA repair rates. Ongoing investigations are assessing the contribution of each of these factors in determining the amounts of adducts. Although there is a positive association between adduct levels and tumor-initiating potency in many, but not all, studies using animal models (35), it is not known whether such an association exists in human carcinogenesis.
Future Research Needs
First, we need to validate current methodology to detect carcinogen-DNA adducts as to specificity, sensitivity, interlaboratory reproducibility, etc. This will require a coordinated effort similar to that developed for validating other "short-term" assays. Because humans are usually exposed to a variety of chemical carcinogens at poorly defined doses and timeframes, the amount of adduct measured at any one time will be a composite of past exposure and the other determinants of carcinogen-DNA adducts discussed above. In addition, methods are needed to detect specific adducts in complex mixtures of carcinogen-DNA adducts. Both the immunological and physical assays have this potential. Mixtures of antibodies to an array of adducts can be used as an initial screen. The physical assays, synchronous fluorescence spectrophotometry and 32P-postlabeling and nucleotide chromatography, may be especially suited for analysis of a mixture of adducts in a biological sample. "Fingerprints" of computer-generated contour maps of spectra obtained by three-dimensional synchronous fluorescence spectrophotometry and two-dimensional autoradiograms of chromatographed 32P-labeled nucleotides may be stored in computer libraries similar to those established for data obtained by mass spectroscopy and by nucleotide and amino acid sequencing techniques. The Laboratory of Human Carcinogenesis, DCE, National Cancer Institute, has initiated such a library of contour maps generated by synchronous fluorescence spectrophotometry. We plan to obtain spectral data in future of carcinogen-DNA adducts, carcinogen-nucleotide adducts, carcinogen-base adducts, and carcinogens and their metabolites that will be available in the future to investigators worldwide through currently available telecommunication links.
Current dogma has directed our efforts to measuring adducts formed by the direct interaction between the activated carcinogen metabolite(s (Table 7) . Animal models will continue to be essential for these studies. Monitoring of individual animals and relating the results of the assays with the tumor incidence, type, location, and latency period in each animal is an area of high priority. Mea- surements of carcinogen-DNA adducts should be incorporated into a battery of other assays (Table 8 ) (1,2).
In vitro models will also be needed for investigations comparing response in tissues and cells from humans to those of experimental animals (Fig. 3) . Fourth, biochemical epidemiological studies are yielding important information, including preliminary results indicating that carcinogen-DNA adducts can be detected in people exposed to carcinogens. More attention can now be directed at more complex experimental designs, e.g., studying the adduct removal rates in people who have ceased smoking tobacco. Cancer patients receiving chemotherapy are an example of a study population in which the dose and regimen of exposure to DNA-damaging agents is well defined. It should be emphasized that (a) laboratory-epidemiological studies are more complicated than those using animal models because of ethical, medical, and legal concerns and (b) carcinogen-DNA adducts are probably related to tumor initiation and to perhaps tumor conversion, which are only two stages in multistage carcinogenesis.
Fifth, the investigations mentioned above will require sustained and substantial financial support from private, industrial, and governmental sources. Both animal and clinical studies are intrinsically long-term in nature and thus costly.
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